By Market & Region

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) has announced the U.S. Food and Drug Administration (FDA) approval of its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for use in patients with asymptomatic severe aortic stenosis (AS). This groundbreaking approval marks the first-ever FDA authorization for TAVR in asymptomatic patients, potentially transforming the treatment landscape for those with this critical condition.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) has announced its participation in the highly anticipated BofA Securities 2025 Health Care Conference, scheduled for Tuesday, May 13, 2025. The company's leadership, including CEO Bernard Zovighian and CFO Scott Ullem, will take part in a fireside chat at 10:40 a.m. Pacific Time. The discussion will be accessible to investors and healthcare professionals through a live webcast available on the Edwards Lifesciences investor relations website at http://ir.edwards.com. An archived version of the session will be accessible later in the day for those unable to attend the live event.

SHERIDAN, WYOMING – May 7, 2025 – A new randomized controlled trial (RCT) has revealed significant advancements in rotator cuff repair, showing that augmentation with the REGENETEN Bioinductive Implant can substantially reduce the risk of re-tears, offering hope for better outcomes in patients undergoing full-thickness rotator cuff repairs. The study's findings have the potential to set a new standard of care in orthopedic surgery.

Understanding the Challenge of Rotator Cuff Repairs

Rotator cuff repairs are among the most commonly performed orthopedic procedures, with an estimated 750,000 surgeries taking place annually in the United States alone. However, the procedure is not without its challenges, as up to 25% of patients experience re-tears, often leading to additional treatments and prolonged recovery times.

SHERIDAN, WYOMING – May 7, 2025 – The growing prevalence of rotator cuff tears, coupled with increasing patient expectations, has sparked a reevaluation of traditional surgical approaches. With more than 750,000 rotator cuff repairs performed annually in the U.S. and the number rising steadily, it’s clear that surgical interventions must evolve to meet the challenges of faster recovery times, improved functional outcomes, and better patient satisfaction. The latest advancements, particularly bioinductive repair using the REGENETEN Bioinductive Implant, present promising alternatives to the established methods of rotator cuff surgery.

SHERIDAN, WYOMING – May 6, 2025 – Zimmer Biomet Holdings, Inc., a global leader in medical technology, has officially launched the "You’ll Be Back" campaign, led by their Chief Movement Officer, Arnold Schwarzenegger. The campaign aims to support millions of individuals suffering from joint pain by offering a unique online community. This initiative seeks to empower people with the knowledge and resources they need to make informed decisions about their mobility and overall health.

The "You’ll Be Back" campaign invites those experiencing limited mobility due to joint pain in areas such as the hip, knee, and shoulder to share their personal stories, join a supportive community, and connect with qualified physicians. Schwarzenegger, an advocate for fitness and mobility, has committed to driving this movement by personally reading submitted stories and selecting participants for a motivational docuseries.

SHERIDAN, WYOMING – May 6, 2025 – The healthcare industry has long relied on traditional training methods for healthcare professionals (HCPs), but recent challenges highlighted by the COVID-19 pandemic have underscored the urgent need for innovation in medical education. Enter Virtual Reality (VR), a transformative tool that is revolutionizing the way healthcare workers are trained and empowering them to deliver better care while improving patient outcomes.

As hospitals and medical institutions continue to face staffing shortages, burnout, and the need for enhanced medical education, VR is emerging as a solution that can help fill critical gaps. By offering immersive, repeatable training experiences, VR technology provides healthcare workers with the opportunity to develop and refine their skills, all while alleviating some of the pressure on experienced professionals and offering tangible benefits to patients.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company), a global leader in medical technology, has announced the induction of Eric Diebold, Ph.D., Vice President and General Manager of Instruments, Software, and Informatics, Biosciences, to the prestigious American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. This distinction, awarded to individuals who have made pioneering contributions to the field, underscores the significant role that Diebold has played in advancing medical and biological engineering, particularly in the realms of photonics, high-speed imaging, and flow cytometry.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company), a global leader in medical technology, has announced its participation in the upcoming Bank of America Securities Health Care Conference, scheduled for Tuesday, May 13, 2025, at 1:00 pm Eastern Time. The live webcast of the presentation will be available on the BD investor relations website, with a replay accessible afterward for those unable to attend the live event.

BD’s Commitment to Innovation in Health Care

BD continues to lead the charge in transforming the medical technology landscape. With a vast portfolio of cutting-edge solutions, BD plays a critical role in advancing medical discovery, diagnostics, and the delivery of care. Through its presentation at the prestigious Bank of America Securities Health Care Conference, BD aims to further demonstrate how its innovations enhance the safety, efficiency, and quality of care for both patients and healthcare providers.

SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, has announced its fiscal 2025 second-quarter financial results, highlighting strategic investments and operational resilience despite a challenging macroeconomic environment. The company reported a revenue increase of 4.5% year-over-year, driven by organic growth, currency-neutral revenues, and a focus on operational efficiency.

BD's continued commitment to innovation and market leadership is evident as it invests in manufacturing capacity and product advancements across its key segments. This article delves into the company’s financial performance, strategic initiatives, and future growth outlook, underlining its position as a driving force in the global healthcare market.

SHERIDAN, WYOMING – May 6, 2025 – Stryker (NYSE: SYK), a leading innovator in medical technology, has announced its participation in the highly anticipated Bank of America Securities 2025 Global Healthcare Conference. The event will take place on Tuesday, May 13, 2025, at the Encore at Wynn Hotel in Las Vegas, Nevada. The company’s presentation, set for 1:40 p.m. Pacific Time, will be delivered by Preston Wells, Vice President and Chief Financial Officer, alongside Jason Beach, Vice President, Finance and Investor Relations.

As a global leader in the medical technology sector, Stryker continues to play a pivotal role in shaping the future of healthcare. This participation in the Bank of America Securities 2025 Global Healthcare Conference marks a significant opportunity for the company to showcase its strategic initiatives, innovations, and contributions to improving healthcare outcomes worldwide.

Key Presentation Highlights

SHERIDAN, WYOMING – May 6, 2025 – Stryker Corporation (NYSE: SYK) has announced its operating results for the first quarter of 2025, showing significant growth in both reported and organic sales, underscoring the company’s strong market performance. The global leader in medical technology posted a notable 11.9% increase in net sales, achieving $5.9 billion, with organic sales growth reaching 10.1%.

SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific Corporation (NYSE: BSX) has reported strong financial results for the first quarter of 2025, driven by sustained product demand, successful execution of its innovation strategy, and solid geographic performance. The company posted net sales of $4.663 billion, reflecting a 20.9% year-over-year increase on a reported basis, exceeding its own guidance range and affirming its leadership position in the global medical device sector.

Double-Digit Revenue Growth Across Segments and Regions

Boston Scientific achieved broad-based momentum across its business units and global markets:

• MedSurg segment delivered 11.7% reported growth (12.8% operational, 5.3% organic).
• Cardiovascular segment saw standout performance with 26.2% reported growth (27.6% operational, 25.6% organic).

Regional growth highlights included:

SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific Corporation (NYSE: BSX) has announced a major leadership transition, with Executive Vice President and Chief Financial Officer Dan Brennan set to retire after nearly three decades with the company. Brennan will step down from the CFO role at the end of June and continue serving as a senior advisor through early October 2025, as Jon Monson, currently Senior Vice President of Investor Relations, is appointed to succeed him.

Leadership Change Marks a Strategic Financial Milestone

SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific has announced landmark 12-month results from the second phase of its ADVANTAGE AF study, revealing that the FARAPULSE™ Pulsed Field Ablation (PFA) System has successfully met all primary safety and efficacy endpoints in patients with persistent atrial fibrillation (AF). The data, unveiled at the PFA Live Case Summit in San Diego and published in Circulation, mark a strategic leap forward in the treatment of complex cardiac arrhythmias using non-thermal ablation technology.

Clinical Advancements in Treating Persistent AF

SHERIDAN, WYOMING – May 6, 2025 – Canon has announced a $1 million donation to the American Red Cross to support relief efforts for the communities devastated by the recent California wildfires, reaffirming the company’s deep-rooted commitment to corporate social responsibility and U.S. community support.

The financial contribution, jointly made by Canon Inc. and Canon Medical Systems USA, will help provide immediate aid and long-term recovery services, including food, emergency shelter, critical supplies, and medical assistance. This move underscores Canon’s ongoing support of American communities and highlights California’s strategic importance within Canon’s business ecosystem.

Corporate Responsibility in Action

Canon’s leadership emphasized that the donation reflects the company’s core philosophy of Kyosei—living and working together for the common good.

SHERIDAN, WYOMING – May 6, 2025 – Canon Medical Systems Corporation has announced the global launch of Aplio beyond, a next-generation, premium ultrasound solution designed to meet the rigorous demands of modern imaging centers, hospitals, and specialized medical practices. The introduction marks a strategic advancement in Canon’s diagnostic imaging portfolio, offering clinicians a robust system that balances performance, efficiency, and sustainability.

Engineered to support high patient volumes and complex clinical procedures, Aplio beyond integrates Canon’s most advanced imaging technologies with ergonomic design and AI-powered workflow enhancements. Its development reflects growing industry demand for smarter, greener medical devices that improve both patient care outcomes and operational ROI.

Delivering Imaging Excellence with Operational Precision

SHERIDAN, WYOMING – May 6, 2025 – Canon Inc. has once again solidified its standing in the global design arena by winning the prestigious iF Design Award for the 31st consecutive year. In a milestone achievement, Canon’s Adastra2 series of semiconductor and electrical component manufacturing equipment claimed the coveted Gold Award—underscoring the company's sustained leadership in industrial innovation and product design.

This year's recognition, granted by Germany’s iF International Forum Design GmbH, saw 111 Canon Group products awarded across categories. The Gold Award for the Adastra2 series marks a strategic victory for Canon as it continues to align high-performance manufacturing systems with world-class design standards—a move that positions the company at the forefront of both operational and aesthetic excellence in industrial equipment.

A Strategic Win in the Semiconductor Manufacturing Space

SHERIDAN, WYOMING – May 6, 2025 – IBM (NYSE: IBM) has announced a landmark $150 billion investment in the United States over the next five years, reinforcing its leadership in high-performance computing, artificial intelligence (AI), and advanced manufacturing. The initiative includes a $30 billion commitment to research and development, ensuring that America remains at the forefront of next-generation technologies such as quantum computing and mainframe systems.

This strategic infusion of capital underscores IBM's long-standing dedication to domestic innovation and its central role in driving the U.S. digital economy. As one of the largest technology employers in the country, IBM’s move is poised to stimulate job creation, enhance national security, and strengthen global competitiveness in critical tech sectors.

Pioneering the Future of Computing

SHERIDAN, WYOMING – May 6, 2025 – Marriott International has announced its agreement to acquire citizenM, a distinctive and tech-forward lifestyle brand, in a move that significantly strengthens its global presence in the select-service and lifestyle hotel segment. This $355 million acquisition underscores Marriott's continued focus on delivering diversified, design-forward lodging experiences and positions the company to tap into evolving traveler preferences and unlock new revenue streams.

Strategic Expansion of Lifestyle Offerings

With this acquisition, Marriott enhances its capabilities to serve a fast-growing market segment: value-conscious, design-savvy, and tech-oriented travelers. The citizenM brand, founded in 2008, currently operates 36 hotels with 8,544 rooms across the U.S., Europe, and Asia Pacific, including major urban hubs like New York, London, Paris, and Rome.

SHERIDAN, WYOMING – May 6, 2025 – Anheuser-Busch, the iconic American brewer behind Budweiser, Bud Light, and Stella Artois, has announced the production of its 100 millionth can of emergency drinking water for disaster-stricken communities across the United States—marking a significant milestone in its longstanding commitment to disaster relief and corporate social responsibility.

$6 Million Investment Strengthens U.S. Disaster Response Capabilities

Coinciding with the milestone, Anheuser-Busch revealed a strategic $6 million investment into its Fort Collins, Colorado brewery to enhance both beer and emergency water production capabilities. The expansion is designed to strengthen the brewer’s operational flexibility and speed of response in national emergencies, while maximizing ROI through more agile supply chain performance.